CD274 and lung carcinoma: Recently, immunotherapy by checkpoint blockade directed against the PD-1/PD-L1 pathway has shown remarkable antitumor responses in patients with advanced melanoma, lung cancer, and other cancers with durable clinical responses [23, 25, 57, 58].